Listed by the USPTO as HEITMEIER, KENDALL NICOLE
Tech Center 3700 • Art Units: 1621 1625 3781
This examiner grants 65% of resolved cases
HEITMEIER, KENDALL NICOLE is assigned to tech center 3700 and art unit 1621. The record includes 43 resolved cases and an allowance rate of 65.1%. The median time to allowance is 1,396 days, while interviews correspond with a 41.1% lift. The small record limits broad conclusions, but the interview figure identifies examiner engagement as a potentially important case-management tool.
The represented companies are University of Florida Research Foundation Inc., VERADERMICS INCORPORATED, and Dana-Farber Cancer Institute Inc. The listed firms are CANTOR COLBURN LLP - UPL LIMITED, MCCARTER & ENGLISH, LLP BOSTON, and ArentFox Schiff, LLP & DFCI. Practitioners may prepare interviews early and maintain alternative claim positions during the extended path to allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17802872 | COMPOUNDS THAT MODULATE ANTI-TUMOR IMMUNITY AND METHODS OF DOING THE SAME | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18737742 | MATERIALS FOR OPTOELECTRONIC APPLICATIONS | Non-Final OA | The Regents of the University of Michigan |
| 18686168 | COMPOSITIONS AND METHODS FOR TREATMENT OF ALOPECIA AREATA | Non-Final OA | VERADERMICS INCORPORATED |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18725593 | BICYCLIC INHIBITORS OF NICOTINAMIDE NMETHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18725495 | POTENT AND SELECTIVE SMARCA2 DEGRADING CHIMERIC MOLECULES AS CANCER THERAPEUTICS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17768344 | COMPOSITIONS AND METHODS OF TREATMENT FOR INHIBITING CAPILLARY TUBE REGRESSION | Final Rejection | University of South Florida |
| 18686007 | OIL-IN-WATER EMULSION COSMETIC | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18158670 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | Non-Final OA | University of Houston System |
| 18034890 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | Non-Final OA | Janssen Pharmaceutica NV |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Non-Final OA | VORONOI INC. |
| 18260567 | PROCESS FOR PREPARATION OF INSECTICIDAL ANTHRANILAMIDES | Final Rejection | UPL LIMITED |
| 18249209 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Final Rejection | MEDIC Life Sciences Inc. |
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | Final Rejection | SHANGHAI KUNHENG PHARMA-TECH CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.1% of resolved applications examined by Kendall Nicole Heitmeier were allowed (43 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +41.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kendall Nicole Heitmeier took 1,396 days on average from filing to allowance.
Kendall Nicole Heitmeier examines applications in Art Unit 1621 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
